[EN] PHENYL-3,4-DIHYDROISOQUINOLIN-2(1H)-YL-ETHAN-1-ONE DERIVATIVES AS DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] DÉRIVÉS DE PHÉNYL-3,4-DIHYDROISOQUINOLIN-2(1H)-YL-ETHAN-1-ONE EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR D1 DE LA DOPAMINE
申请人:LILLY CO ELI
公开号:WO2022076418A1
公开(公告)日:2022-04-14
The invention provides certain (phenyl)-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one related compounds of formula I as D1 positive allosteric modulators (PAMs), and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I, to treat certain symptoms of dopaminergic CNS disorders including Parkinson's disease, Schizophrenia, ADHD or Alzheimer's disease.
该发明提供了公式I中的某些(苯基)-3,4-二氢异喹啉-2(1H)-基)乙酮相关化合物,作为D1正向助剂调节剂(PAMs),以及其制药组合物。该发明还提供使用公式I中的化合物的方法,以治疗多巴胺能中枢神经系统疾病的某些症状,包括帕金森病、精神分裂症、注意力缺陷多动障碍或阿尔茨海默病。